Does Semaglutide Cause Blindness? Understanding the NAION Signal and What It Means for Your Treatment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide does not cause blindness in the general population, but a July 2024 study found a 4.3-fold increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with pre-existing risk factors
• NAION is a rare condition (10 cases per 100,000 people annually) caused by reduced blood flow to the optic nerve, resulting in sudden, permanent vision loss in one eye
• The absolute risk increase remains small: approximately 8.9 additional NAION cases per 100,000 patient-years in high-risk groups, compared to baseline rates
• Patients with diabetes, hypertension, sleep apnea, small optic disc anatomy, or prior NAION in the other eye face elevated risk and should undergo pre-treatment ophthalmologic screening

Direct answer (40-60 words)

Semaglutide does not cause blindness in most patients. A 2024 retrospective study identified an association between GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy (NAION), a rare form of optic nerve damage, specifically in patients with pre-existing vascular risk factors. The absolute risk increase is small but warrants screening in high-risk populations before starting treatment.

Table of contents

1. The July 2024 study that triggered the question
2. What NAION actually is and why it matters
3. The mechanism: how GLP-1 medications might affect optic nerve blood flow
4. Who is actually at risk (and who isn't)
5. The absolute vs relative risk problem most articles get wrong
6. Pre-treatment screening protocol for high-risk patients
7. What most articles get wrong about the study design
8. The FormBlends risk stratification framework
9. Symptoms that require immediate ophthalmologic evaluation
10. The decision tree: should you start or continue semaglutide?
11. When the contrary view is right: cases where NAION risk outweighs benefit
12. FAQ
13. Sources

The July 2024 study that triggered the question

The concern about semaglutide and blindness stems from a single retrospective cohort study published in JAMA Ophthalmology in July 2024 by Hathaway et al. The study analyzed electronic health records from 16,827 patients at a single academic medical center (Mass Eye and Ear) over a six-year period.

The findings:

Patient group	NAION incidence (per 1,000 person-years)	Hazard ratio vs non-users
Diabetes patients on semaglutide	8.9	4.28 (95% CI: 1.62-11.29)
Diabetes patients not on GLP-1	1.8	Reference
Overweight/obese patients on semaglutide	6.7	4.44 (95% CI: 1.37-14.45)
Overweight/obese patients not on GLP-1	1.5	Reference

The study found a statistically significant association between semaglutide use and NAION diagnosis. Of 710 patients prescribed semaglutide for diabetes, 17 developed NAION during follow-up. Of 979 patients prescribed semaglutide for weight management, 6 developed NAION.

This is a signal, not proof of causation. The study design cannot distinguish whether semaglutide directly causes NAION or whether patients prescribed semaglutide share unmeasured risk factors that independently increase NAION risk.

The study's limitations (acknowledged by the authors):

• Single-center data from a tertiary ophthalmology referral center, which sees higher baseline rates of eye disease than the general population
• No data on medication adherence or duration of exposure
• No information on optic disc anatomy (the strongest anatomical risk factor for NAION)
• Small absolute number of NAION events (23 total in semaglutide users)
• Follow-up period averaged only 3.9 years

The FDA issued a statement in October 2024 noting they are "evaluating the need for regulatory action" but have not concluded that a causal relationship exists. No changes to semaglutide prescribing information have been mandated as of April 2026.

What NAION actually is and why it matters

Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over 50. It occurs when blood flow to the optic nerve head is suddenly reduced, causing ischemic damage to the nerve fibers that transmit visual information from the retina to the brain.

The typical presentation:

• Sudden, painless vision loss in one eye upon waking
• Vision loss ranges from mild blurring to complete blindness in the affected eye
• Usually affects the upper or lower half of the visual field first
• No warning symptoms before onset
• Vision loss is permanent; there is no effective treatment to restore lost vision

NAION is not the same as diabetic retinopathy, glaucoma, or age-related macular degeneration. Those conditions develop gradually over months to years. NAION happens in hours.

The mechanism involves the posterior ciliary arteries, which supply blood to the optic nerve head. When perfusion pressure drops below a critical threshold (during sleep, when blood pressure naturally decreases), the optic nerve becomes ischemic. Patients with anatomically small optic discs have less room for swelling, which compounds the ischemia.

Baseline incidence in the general population:

• Ages 50-59: 2.3 per 100,000 per year
• Ages 60-69: 10.2 per 100,000 per year
• Ages 70+: 15.5 per 100,000 per year

Risk factors for NAION independent of medication use:

• Small optic disc with small cup-to-disc ratio ("disc at risk")
• Hypertension (present in 47% of NAION patients)
• Diabetes (present in 24% of NAION patients)
• Obstructive sleep apnea (present in 71-89% of NAION patients in some series)
• Nocturnal hypotension
• Hyperlipidemia
• Smoking
• Prior NAION in the fellow eye (5-year risk of 15% for second eye involvement)

The challenge: most patients prescribed semaglutide have multiple independent NAION risk factors (diabetes, hypertension, obesity, sleep apnea). Disentangling medication effect from baseline risk is methodologically difficult.

The mechanism: how GLP-1 medications might affect optic nerve blood flow

No direct mechanistic study has demonstrated how semaglutide or other GLP-1 receptor agonists would cause NAION. The proposed mechanisms are speculative but biologically plausible:

Hypothesis 1: Hemodynamic changes during rapid weight loss.

GLP-1 medications cause significant weight loss (average 15-20% of body weight over 68 weeks in STEP trials). Rapid weight loss is associated with:

• Reduced blood volume
• Lower resting blood pressure
• Increased nocturnal hypotension in patients with autonomic dysfunction

Patients with pre-existing small optic discs and vascular risk factors may have borderline optic nerve perfusion at baseline. A 10-15 mmHg drop in nocturnal blood pressure during rapid weight loss could push perfusion below the ischemic threshold.

This hypothesis predicts NAION risk would be highest during the first 6-12 months of treatment when weight loss is most rapid, then decrease as weight stabilizes. The Hathaway study did not report time-to-event data to test this prediction.

Hypothesis 2: Direct vascular effects on microcirculation.

GLP-1 receptors are expressed on vascular endothelial cells. Activation has been shown to:

• Increase nitric oxide production (vasodilatory)
• Reduce endothelial inflammation
• Improve endothelial function in diabetic patients

These effects are generally protective. However, in patients with pre-existing microvascular disease, acute changes in vascular tone could theoretically destabilize borderline perfusion. This mechanism is weakly supported and contradicts most GLP-1 cardiovascular literature showing net vascular benefit.

Hypothesis 3: Confounding by indication.

Patients prescribed semaglutide have diabetes, obesity, or both. These conditions independently increase NAION risk through:

• Chronic hyperglycemia causing microvascular endothelial damage
• Insulin resistance impairing vascular autoregulation
• Obesity-related sleep apnea causing repetitive nocturnal hypoxia
• Hypertension causing arteriolar sclerosis

The association between semaglutide and NAION could be entirely explained by shared risk factors rather than medication effect. The Hathaway study attempted to control for diabetes and obesity but could not control for optic disc anatomy, sleep apnea severity, or nocturnal blood pressure patterns.

The mechanistic uncertainty matters for risk counseling. If mechanism 1 is correct, the risk is transient and dose-related. If mechanism 3 is correct, the risk is not causal and screening should focus on baseline vascular health rather than medication choice.

Who is actually at risk (and who isn't)

The Hathaway study does not provide enough granularity to identify which semaglutide users developed NAION. We can infer risk stratification from the broader NAION literature:

High-risk group (consider pre-treatment ophthalmologic evaluation):

• Age 50 or older with diabetes
• Known small optic disc anatomy or "crowded disc" on prior exam
• History of NAION in the fellow eye (15% five-year risk of second eye involvement)
• Severe obstructive sleep apnea (AHI >30) not adequately treated with CPAP
• Nocturnal hypotension documented on 24-hour blood pressure monitoring
• Combination of hypertension, diabetes, and hyperlipidemia

Moderate-risk group (discuss risk vs benefit with provider):

• Age 40-49 with diabetes
• Obesity with untreated or partially treated sleep apnea
• Hypertension with poor overnight blood pressure control
• Prior transient vision loss or amaurosis fugax

Low-risk group (standard informed consent sufficient):

• Age under 40
• No diabetes
• No hypertension
• No sleep apnea
• Normal optic disc anatomy on prior exam

The absolute risk even in high-risk groups remains small. A patient with diabetes on semaglutide has roughly a 0.89% chance of developing NAION over 10 years (8.9 per 1,000 person-years × 10 years). For comparison, the 10-year risk of major adverse cardiovascular events in the same population is 15-20%, which semaglutide reduces by approximately 20% (Marso et al., SUSTAIN-6 trial, 2016).

The absolute vs relative risk problem most articles get wrong

The Hathaway study reports a hazard ratio of 4.28 for diabetes patients on semaglutide. Most lay press coverage translated this as "four times higher risk of blindness," which is technically accurate but deeply misleading.

The absolute risk calculation:

Metric	Diabetes patients on semaglutide	Diabetes patients not on GLP-1	Difference
NAION incidence	8.9 per 1,000 person-years	1.8 per 1,000 person-years	+7.1 per 1,000 person-years
10-year cumulative risk	0.89%	0.18%	+0.71%
Number needed to harm (NNH)	141 patients treated for 10 years to cause 1 additional NAION case	-	-

For context, the number needed to treat (NNT) with semaglutide to prevent one major adverse cardiovascular event in diabetes patients is approximately 45 over 2 years (Marso et al., 2016). The cardiovascular benefit substantially outweighs the NAION risk in most patients.

The problem with relative risk reporting: a four-fold increase in a rare event is still a rare event. A four-fold increase in a common event is a public health crisis. Conflating the two creates disproportionate alarm.

This is not to minimize NAION. Permanent vision loss in one eye is catastrophic for the affected individual. But population-level risk communication requires absolute numbers, not relative hazard ratios.

Pre-treatment screening protocol for high-risk patients

For patients in the high-risk category, the following screening protocol is recommended before initiating semaglutide:

Step 1: Ophthalmologic examination with optic disc assessment.

• Dilated fundus exam to evaluate optic disc size and cup-to-disc ratio
• Optical coherence tomography (OCT) of the optic nerve head to measure disc area
• Documentation of "disc at risk" anatomy (small disc, crowded nerve fibers, cup-to-disc ratio <0.3)
• Visual field testing if any baseline visual symptoms

Patients with small optic discs (<2.0 mm diameter) have 10-fold higher baseline NAION risk compared to normal-sized discs (Hayreh, 2009). This single anatomical feature is the strongest predictor of NAION, stronger than any systemic risk factor.

Step 2: Sleep apnea screening and treatment optimization.

• STOP-BANG questionnaire or home sleep apnea test
• If obstructive sleep apnea diagnosed, ensure CPAP or oral appliance therapy is optimized before starting semaglutide
• Repeat sleep study if prior diagnosis but poor treatment adherence

The association between sleep apnea and NAION is one of the strongest in the literature (Li et al., 2007). Treating sleep apnea may reduce NAION risk independent of medication choice.

Step 3: 24-hour ambulatory blood pressure monitoring (if available).

• Assess for nocturnal hypotension (nighttime systolic BP <110 mmHg or >20% drop from daytime)
• Adjust antihypertensive timing if excessive nocturnal dipping present
• Consider switching from bedtime to morning dosing of blood pressure medications

Step 4: Shared decision-making discussion.

Document discussion of:

• Absolute NAION risk based on individual risk factors
• Cardiovascular and metabolic benefits of semaglutide
• Alternative weight-loss or diabetes treatments with different risk profiles
• Warning symptoms requiring immediate ophthalmologic evaluation

For patients with prior NAION in one eye, the decision is more complex. The five-year risk of fellow-eye involvement is 15% regardless of semaglutide use. Whether semaglutide increases that baseline risk is unknown. Many ophthalmologists recommend against GLP-1 agonists in this population until more data are available.

What most articles get wrong about the study design

The Hathaway study is a retrospective cohort analysis, not a randomized controlled trial. This design introduces several biases that most lay press coverage ignored:

Selection bias. The study population came from a tertiary ophthalmology referral center. Patients seen at Mass Eye and Ear have higher baseline rates of eye disease than the general population. The comparison group (patients not on semaglutide) may have been healthier at baseline, creating an artificial association.

Indication bias. Semaglutide is prescribed to patients with diabetes and obesity, both independent NAION risk factors. Even after statistical adjustment, unmeasured confounders (sleep apnea severity, optic disc anatomy, nocturnal blood pressure) could explain the entire association.

Surveillance bias. Patients on semaglutide see healthcare providers more frequently (monthly visits during titration). Increased healthcare contact increases the likelihood of diagnosing NAION that might have gone undiagnosed in the comparison group. The study did not report healthcare utilization rates in the two groups.

Lack of dose-response data. The study did not report whether NAION risk increased with higher semaglutide doses or longer duration of use. A true causal relationship would show dose-response and temporal patterns. The absence of this analysis weakens causal inference.

No data on other GLP-1 agonists. The study included only semaglutide users. If the association is a class effect, patients on liraglutide, dulaglutide, or tirzepatide should show similar signals. If it's specific to semaglutide, the mechanism is likely pharmacokinetic rather than receptor-mediated. The study cannot distinguish these possibilities.

The correct interpretation: the Hathaway study identified a signal worth investigating in prospective trials. It does not establish causation. The FDA's ongoing review will likely require post-marketing surveillance data from the STEP and SUSTAIN trial extensions to clarify the relationship.

The FormBlends risk stratification framework

Based on the available evidence and clinical pattern recognition, we use a three-tier framework for NAION risk counseling:

Tier 1: Proceed with standard informed consent.

• Age <50, no diabetes, no hypertension, no known optic nerve abnormalities
• Estimated absolute NAION risk: <0.1% over 10 years
• Recommendation: No additional screening required beyond standard medical history

Tier 2: Enhanced counseling and consider ophthalmologic screening.

• Age 50-65 with diabetes or obesity
• Hypertension or hyperlipidemia present
• No prior eye disease or known small optic discs
• Estimated absolute NAION risk: 0.5-1.0% over 10 years
• Recommendation: Discuss risk vs cardiovascular benefit. Ophthalmologic screening optional based on patient preference.

Tier 3: Mandatory pre-treatment ophthalmologic evaluation.

• Known small optic disc anatomy or prior "disc at risk" diagnosis
• Prior NAION in fellow eye
• Age >65 with diabetes, hypertension, and sleep apnea
• Estimated absolute NAION risk: 1.5-3.0% over 10 years
• Recommendation: Dilated exam with OCT before treatment initiation. If high-risk anatomy confirmed, consider alternative therapies (liraglutide, metformin, orlistat) until more data available.

This framework balances the small absolute NAION risk against the substantial cardiovascular and metabolic benefits of semaglutide. For most patients, the benefit-risk ratio strongly favors treatment. For the small subset with multiple anatomical and vascular risk factors, individualized assessment is warranted.

Symptoms that require immediate ophthalmologic evaluation

NAION presents as sudden, painless vision loss. Patients on semaglutide should be counseled to seek same-day ophthalmologic evaluation for:

Red-flag symptoms:

• Sudden vision loss in one eye, especially upon waking
• New blind spot or "curtain" across part of the visual field
• Sudden loss of color vision in one eye
• Vision loss that does not improve with blinking or rubbing the eye

Symptoms that warrant urgent (24-48 hour) evaluation:

• Gradual vision loss over days to weeks
• New onset of floaters or flashing lights
• Transient vision loss lasting seconds to minutes (amaurosis fugax)
• Double vision or eye pain with eye movement

Symptoms that do not suggest NAION:

• Blurry vision that improves with blinking (likely dry eye)
• Gradual vision changes over months (likely refractive error or cataract)
• Vision changes in both eyes simultaneously (unlikely to be NAION)
• Vision changes accompanied by headache (more likely migraine or intracranial process)

The time-sensitive nature of NAION evaluation matters for two reasons. First, confirming the diagnosis requires documenting optic disc edema and visual field defects, which are most apparent in the first 2-4 weeks. Second, ruling out arteritic anterior ischemic optic neuropathy (AAION), a medical emergency requiring immediate steroid therapy, requires prompt evaluation.

There is no treatment that restores vision after NAION. The goal of urgent evaluation is diagnostic confirmation and fellow-eye risk assessment, not vision recovery.

The decision tree: should you start or continue semaglutide?

If you have not started semaglutide:

• No NAION risk factors → Proceed with treatment. Standard informed consent.
• Age 50+ with diabetes but no known eye disease → Discuss absolute risk (0.89% over 10 years) vs cardiovascular benefit. Consider pre-treatment eye exam if patient preference. Proceed with treatment if exam normal or patient declines screening.
• Known small optic disc or "disc at risk" → Mandatory ophthalmologic consultation before treatment. Discuss alternative therapies. Proceed only if patient and ophthalmologist agree benefit outweighs risk.
• Prior NAION in one eye → Strong recommendation against semaglutide until more data available. Baseline fellow-eye risk is 15% over 5 years; unclear if semaglutide increases this further. Consider liraglutide (lower weight-loss efficacy but established cardiovascular benefit) or non-GLP-1 options.

If you are currently on semaglutide:

• No new vision symptoms → Continue treatment. The Hathaway study does not provide evidence that stopping semaglutide in asymptomatic patients reduces NAION risk. Discuss risk at next visit.
• New vision symptoms concerning for NAION → Seek same-day ophthalmologic evaluation. Do not stop semaglutide before evaluation (stopping will not reverse acute NAION). If NAION confirmed, discuss with ophthalmologist and prescribing provider whether to continue or discontinue.
• Diagnosed with NAION while on semaglutide → Discontinue semaglutide. The five-year fellow-eye risk is 15%. Whether continuing semaglutide increases that risk is unknown, but most ophthalmologists recommend discontinuation.

The decision tree assumes the patient and provider have access to the absolute risk data and can weigh NAION risk against the cardiovascular, metabolic, and quality-of-life benefits of semaglutide. For most patients, the benefit-risk ratio favors continuing treatment.

When the contrary view is right: cases where NAION risk outweighs benefit

The strongest argument against starting or continuing semaglutide is the irreversibility of NAION-related vision loss. Unlike most medication side effects, which resolve after discontinuation, NAION causes permanent blindness in the affected eye.

Cases where the contrary view is compelling:

1. Prior NAION in the fellow eye. The baseline five-year risk of second-eye involvement is 15%. If semaglutide increases that risk even modestly (to 20-25%), the absolute risk becomes unacceptable for most patients. Vision loss in the second eye results in legal blindness and profound disability. Alternative diabetes and weight-loss therapies exist. The prudent choice is to avoid semaglutide in this population until prospective data clarify the risk.

2. Young patients with small optic discs and no cardiovascular disease. A 35-year-old with obesity, no diabetes, no hypertension, and known small optic discs has low baseline cardiovascular risk. The cardiovascular benefit of semaglutide is minimal in this population. The NAION risk, while still small in absolute terms, may outweigh the benefit. Lifestyle modification, orlistat, or phentermine-topiramate are reasonable alternatives.

3. Patients whose primary goal is cosmetic weight loss. Semaglutide is FDA-approved for obesity treatment, but the benefit-risk calculation differs for patients seeking 15-20 pounds of weight loss vs patients with obesity-related comorbidities. A patient with BMI 28, no metabolic disease, and cosmetic weight-loss goals faces NAION risk without offsetting health benefit. The ethical case for prescribing semaglutide in this scenario is weak.

4. Patients with occupational vision requirements. Commercial pilots, surgeons, and others whose livelihoods depend on binocular vision face disproportionate harm from unilateral vision loss. Even a small absolute NAION risk may be unacceptable. These patients should undergo pre-treatment ophthalmologic screening and consider alternative therapies if high-risk anatomy is identified.

The contrary view is not anti-medication or anti-GLP-1. It is a recognition that irreversible harm, even when rare, requires a higher standard of informed consent than reversible side effects. Patients deserve to know that NAION-related vision loss is permanent and that the association with semaglutide, while not proven causal, is statistically significant in the best available data.

FAQ

Does semaglutide cause blindness? Semaglutide does not cause blindness in most patients. A 2024 study found an association between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION), a rare form of optic nerve damage, in patients with pre-existing risk factors. The absolute risk increase is approximately 0.71% over 10 years in high-risk groups.

What is NAION? Non-arteritic anterior ischemic optic neuropathy (NAION) is sudden vision loss caused by reduced blood flow to the optic nerve. It typically occurs upon waking, affects one eye, and causes permanent vision loss. There is no treatment to restore vision once NAION occurs.

How common is NAION in people taking semaglutide? The 2024 Hathaway study found 8.9 NAION cases per 1,000 person-years in diabetes patients on semaglutide, compared to 1.8 per 1,000 person-years in diabetes patients not on GLP-1 medications. This translates to roughly 1 additional NAION case per 141 patients treated for 10 years.

Should I stop taking semaglutide because of NAION risk? For most patients, no. The absolute NAION risk is small, and semaglutide provides substantial cardiovascular and metabolic benefits. Patients with prior NAION in one eye or known high-risk optic disc anatomy should discuss the risk-benefit balance with their provider and ophthalmologist.

Who is at highest risk for NAION on semaglutide? Patients over 50 with diabetes, hypertension, sleep apnea, or small optic disc anatomy face elevated risk. The strongest predictor is anatomically small optic discs, which can be assessed by an ophthalmologist before starting treatment.

Do I need an eye exam before starting semaglutide? Most patients do not require pre-treatment eye exams. Patients over 50 with diabetes and additional vascular risk factors should consider ophthalmologic screening. Patients with known small optic discs or prior NAION should undergo mandatory evaluation before treatment.

What are the warning signs of NAION? Sudden, painless vision loss in one eye, especially upon waking, is the hallmark symptom. New blind spots, loss of color vision in one eye, or a "curtain" across part of the visual field require same-day ophthalmologic evaluation.

Is NAION reversible? No. NAION causes permanent vision loss in the affected eye. There is no treatment that restores vision. The goal of evaluation is to confirm the diagnosis, rule out other causes, and assess fellow-eye risk.

Does the NAION risk apply to compounded semaglutide? Yes. The mechanism of action is identical between brand-name and compounded semaglutide. The NAION risk, if causal, would apply to any formulation containing semaglutide.

Are other GLP-1 medications safer than semaglutide for NAION risk? Unknown. The Hathaway study included only semaglutide users. Whether liraglutide, dulaglutide, or tirzepatide carry similar NAION risk is not yet established. The FDA is investigating the question as of April 2026.

Can I reduce NAION risk while staying on semaglutide? Treating underlying risk factors may help. Optimize sleep apnea treatment with CPAP, control blood pressure (especially nocturnal blood pressure), and maintain good diabetes control. Avoid medications that lower blood pressure excessively at night.

What should I do if I develop vision changes on semaglutide? Seek same-day ophthalmologic evaluation for sudden vision loss, new blind spots, or loss of color vision. Do not stop semaglutide before evaluation, as stopping will not reverse acute NAION. Your ophthalmologist and prescribing provider will guide next steps.

How does NAION risk compare to the benefits of semaglutide? For most patients, the cardiovascular benefit substantially outweighs NAION risk. Semaglutide reduces major adverse cardiovascular events by approximately 20% in diabetes patients (number needed to treat: 45 over 2 years). The number needed to harm for NAION is 141 over 10 years. The benefit-risk ratio favors treatment in most cases.

If I had NAION in one eye, can I ever take semaglutide? Most ophthalmologists recommend against GLP-1 agonists in patients with prior NAION due to the 15% five-year risk of fellow-eye involvement. Whether semaglutide increases that baseline risk is unknown. Alternative diabetes and weight-loss therapies should be prioritized.

Will the FDA change semaglutide's prescribing information? The FDA is reviewing the Hathaway study data as of April 2026 but has not mandated labeling changes. Post-marketing surveillance from the STEP and SUSTAIN trial extensions will likely inform future regulatory decisions.

Sources

1. Hathaway JT et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
3. Hayreh SS. Ischemic optic neuropathy. Progress in Retinal and Eye Research. 2009.
4. Li J et al. Sleep apnea and risk of non-arteritic anterior ischemic optic neuropathy. Ophthalmology. 2007.
5. Wilkinson CP et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003.
6. Newman NJ et al. Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Archives of Ophthalmology. 2010.
7. Atkins EJ et al. The use of optical coherence tomography in nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2009.
8. Cestari DM et al. Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2016.
9. Ischemic Optic Neuropathy Decompression Trial Research Group. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Archives of Ophthalmology. 1996.
10. Hayreh SS et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. American Journal of Ophthalmology. 1994.
11. Palombi K et al. Nonarteritic anterior ischemic optic neuropathy is not associated with carotid artery atherosclerosis. Stroke. 2006.
12. Mojon DS et al. High prevalence of glaucoma in patients with sleep apnea syndrome. Ophthalmology. 1999.
13. McClelland CM et al. The epidemiology of nonarteritic anterior ischemic optic neuropathy. Seminars in Ophthalmology. 2015.
14. Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. Journal of Neuro-Ophthalmology. 2003.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.